Private funding hits a five-year low, even as AI-driven drug development, exports and acquisition activity point to resilience in the sector

Private funding hits a five-year low, even as AI-driven drug development, exports and acquisition activity point to resilience in the sector

Investments in Israeli life sciences companies fell sharply in 2025, dropping 40% after a recovery the previous year, according to a report by the Israel Advanced Technology…